Key facts
- It has raised $2.2M; the latest was Later Stage VC ($2.0M) in Mar 2026.
- Notable investors include National Institutes of Health, Mayo Clinic Ventures, Institute for Commercialization of Florida Technology, Multiple Myeloma Research Foundation, National Cancer Institute — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Modulation Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Modulation Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Modulation Therapeutics
Operator of a clinical-stage biotechnology platform designed to create therapies for aggressive solid tumor cancers and liver disease. The company offers a targeted radiotherapeutic with an actinium-based payload directed to melanocortin receptor-expressing tumors and an orally bioavailable stearoyl CoA desaturase inhibitor, enabling patients with refractory solid tumors and liver disease to receive targeted treatments with novel biological mechanisms.
- Sector
- Healthcare
- HQ
- Morgantown, WV, United States
- Founded
- 2011
- Employees
- 3
- Website
- modulationtherapeutics.com/
- Ownership
- Privately Held (backing)
Modulation Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Modulation Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Modulation Therapeutics in its N-PORT filings yet. We sweep new filings monthly.